Cybin Inc (CYBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cybin Inc (CYBN) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-31.95 Million ≈ $-23.11 Million USD) by net assets (CA$273.93 Million ≈ $198.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cybin Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Cybin Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Cybin Inc for a breakdown of total debt and financial obligations.
Cybin Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cybin Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Sanmao Enterprise Group Co Ltd A
SHG:600689
|
-0.024x |
|
Korea Environment Technology Co. LTD
KQ:029960
|
0.041x |
|
Karmarts Public Company Limited
BK:KAMART
|
0.050x |
|
WITHSECURE
HE:WITH
|
0.022x |
|
Byggmax Group AB
ST:BMAX
|
-0.011x |
|
Materialise NV
F:06MA
|
0.041x |
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
-0.003x |
|
Pro Real Estate Investment Trust
TO:PRV-UN
|
0.022x |
Annual Cash Flow Conversion Efficiency for Cybin Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Cybin Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see CYBN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$237.20 Million ≈ $171.59 Million |
CA$-101.30 Million ≈ $-73.28 Million |
-0.427x | -80.93% |
| 2024-03-31 | CA$291.93 Million ≈ $211.18 Million |
CA$-68.91 Million ≈ $-49.85 Million |
-0.236x | +76.00% |
| 2023-03-31 | CA$48.23 Million ≈ $34.89 Million |
CA$-47.43 Million ≈ $-34.31 Million |
-0.983x | -65.65% |
| 2022-03-31 | CA$76.16 Million ≈ $55.09 Million |
CA$-45.21 Million ≈ $-32.70 Million |
-0.594x | -168.68% |
| 2021-03-31 | CA$86.12 Million ≈ $62.30 Million |
CA$-19.03 Million ≈ $-13.76 Million |
-0.221x | +76.90% |
| 2020-03-31 | CA$1.45 Million ≈ $1.05 Million |
CA$-1.38 Million ≈ $-1.00 Million |
-0.956x | -- |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more